enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) shares were up 3.8% during trading on Thursday . The company traded as high as $2.49 and last traded at $2.49. Approximately 2,031 shares changed hands during trading, a decline of 82% from the average daily volume of 11,448 shares. The stock had previously closed at $2.40.
enGene Price Performance
The firm has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $1.32.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- 3 Tickers Leading a Meme Stock Revival
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- Pros And Cons Of Monthly Dividend Stocks
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- How to Invest in Biotech Stocks
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
